Release date: 28 April 2020
Promoter – Financial Intermediary
GALENICUM HEALTH SLLocation
Description
The project will finance the promoter's pharmaceutical RDI and expansion investments in Spain.
Objectives
The EIB loan will be used to support the implementation of the company's strategy. The investments are expected to support the promoter's competitiveness and growth.
Sector(s)
- Industry - Manufacturing
Proposed EIB finance (Approximate amount)
EUR 20 million
Total cost (Approximate amount)
EUR 50 million
Environmental aspects
All aspects related to the environmental impact and permits will be verified during the project's appraisal.
Procurement
The promoter has been assessed by the EIB as being a private company not operating in the utilities sector and not having a status of a contracting entity, thus not being subject to EU rule on public procurement.
Status
Signed - 14/01/2021
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).